Immuneering Corporation (IMRX)

Immuneering Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	58.23	128.65	36.14	59.41	72.64	74.89
Short-Term Investments	87.18	44.19	-	26.26	32.89	74.31
Cash & Short-Term Investments	145.41	172.83	36.14	85.67	105.52	149.2
Cash Growth	-36.10%	378.17%	-57.81%	-18.82%	-29.27%	302.26%
Receivables	-	-	-	-	0.01	0.25
Prepaid Expenses	5.31	3.41	3.44	3.42	3.21	2.89
Total Current Assets	150.71	176.25	39.59	89.08	108.75	152.33
Property, Plant & Equipment	3.85	4.26	4.79	5.4	5.78	6.13
Long-Term Investments	20.71	44.18	-	-	-	1
Goodwill	6.69	6.69	6.69	6.69	6.69	6.7
Other Intangible Assets	0.3	0.32	0.35	0.38	0.41	0.44
Other Long-Term Assets	0.3	0.28	1.3	1.03	0.74	0.1
Total Assets	182.56	231.99	52.71	102.58	122.37	166.7

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	2.76	1.54	1.96	2.11	3.15	1.39
Accrued Expenses	7.5	7.84	4.97	5.17	4.5	3.97
Current Portion of Leases	0.45	0.4	0.34	0.3	0.38	0.27
Other Current Liabilities	0.09	0.29	0.23	0.26	0.02	-
Total Current Liabilities	10.79	10.07	7.5	7.85	8.05	5.63
Long-Term Leases	3.09	3.43	3.82	4.16	4.46	5.09
Total Liabilities	13.88	13.5	11.33	12.01	12.52	10.72

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.06	0.06	0.03	0.03	0.03	0.03
Additional Paid-In Capital	504.41	498.66	265.65	253.81	219.64	215.28
Retained Earnings	-335.24	-280.32	-224.3	-163.26	-109.79	-59.27
Comprehensive Income & Other	-0.55	0.08	-	-0	-0.03	-0.05
Total Common Equity	168.68	218.48	41.39	90.58	109.85	155.98
Shareholders' Equity	168.68	218.48	41.39	90.58	109.85	155.98
Total Liabilities & Equity	182.56	231.99	52.71	102.58	122.37	166.7

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	3.53	3.82	4.16	4.46	4.84	5.36
Net Cash (Debt)	162.58	213.19	31.98	81.2	100.68	144.83
Net Cash Growth	-27.30%	566.60%	-60.61%	-19.35%	-30.48%	297.13%
Net Cash Per Share	2.51	4.84	1.07	2.86	3.82	10.64
Filing Date Shares Outstanding	64.76	64.65	35.89	29.28	26.44	26.38
Total Common Shares Outstanding	64.76	64.65	31.05	29.27	26.42	26.32
Working Capital	139.92	166.17	32.08	81.24	100.69	146.7
Book Value Per Share	2.60	3.38	1.33	3.09	4.16	5.93
Tangible Book Value	161.69	211.47	34.35	83.51	102.75	148.84
Tangible Book Value Per Share	2.50	3.27	1.11	2.85	3.89	5.65
Machinery	2.15	2	1.91	1.83	1.5	0.83
Construction In Progress	-	0.04	-	-	-	-
Leasehold Improvements	0.32	0.3	0.3	0.3	0.29	0.15

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Oct 29, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 4, 2026

Data Sources Report a data error